drugset / Trial / NCT02253316
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Phase 2
Active not recruiting
236 enrolled
Washington University School of Medicine
Millennium Pharmaceuticals, Inc. · collabMultiple Myeloma Research Consortium · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib, lenalidomide (also called Revlimid), and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide.
Timeline
- Start
- 2015-01-20
- Primary completion
- 2020-02-05
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Background | Dexamethasone | Small molecule | 40 mg | — |